Author: George Underwood

Otsuka’s Deltyba could cure visceral leishmaniasis; new, highly effective breast cancer drug takes another step forward; positive results for GSK and Innovia’s Relvar Ellipta, and Genentech’s Gazyva

Daiichi Sankyo has announced that it will not proceed with the second part of its phase 3 study for its lung cancer drug patritumab.

Janssen has slammed a draft decision by the National Institute for Health and Care Excellence rejecting NHS funding for its cancer drug Imbruvica to treat patients with Chronic Lymphocytic Leukaemia (CLL).

$1bn sales predicted for Lilly’s plaque psoriasis drug; Boehringer collaborates for schizophrenia; Daiichi gets Japan license for cardiac regeneration medicine

This week’s round-up of drug approvals and HTA news includes: an SMC recommendations for AbbVie’s Humira; decentralised approval in five EU countries for Martindale’s Prenoxad injection; and an EU thumbs up for BMS’ Opdivo and Yervoy